Latest Life Sciences News

EZZ Life Science Holdings Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the six months ending December 2024, signaling steady returns for shareholders.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Lendlease Group has reported a robust turnaround in its half-year results, posting an operating profit after tax of $122 million and advancing its strategic capital recycling initiatives. The company is on track to reduce gearing and enhance operational efficiency amid ongoing market challenges.

Lendlease Group has reported a statutory profit after tax of $48 million for the half year ended December 2024, reversing a prior loss and announcing a 6.0 cent interim distribution. The company is advancing key asset sales including Capella Capital and its US Military Housing business as part of its strategic transformation.

Charter Hall Social Infrastructure REIT delivered a solid 2025 half-year performance, maintaining distribution guidance while enhancing its portfolio through key acquisitions and divestments. The REIT’s outlook brightens with an increased full-year distribution forecast.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Invion Limited has marked significant progress in its cancer treatment pipeline, dosing the first patient in a pivotal skin cancer trial and reporting encouraging prostate cancer results, while securing fresh funding to support ongoing development.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.